The Financial Express6h
Q3FY25: GSK pharma’s profit surges 4X to Rs 229 crore; Revenue up 18 percent
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...
India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
Cutting NIH funding puts my life on the line — and maybe yours as well
Private investment in pharmaceutical research can't replace the NIH. Both public investment and the private sector are needed ...
cnbctv187h
GSK Pharma Q3 Results: Strong revenue, EBITDA growth; vaccines segment gains
GSK Pharma reported strong Q3 performance with revenue up 18% and EBITDA rising 34%. Key brands, including Augmentin and ...